Oncology Nursing Drug Handbook
iOS Universel / Medecine
"Try before you buy" - Download the FREE App, which includes sample content. An in-App purchase is required to unlock all content.
Created especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential resource provides valuable information on effective symptom management, patient education, and chemotherapy administration.
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.
Key Features
* Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
* Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
* Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
* Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
* New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)
No internet connection is required to access the content after the initial download. Find information quickly using powerful SmartSearch technology. Search part of term for those hard to spell medical terms.
Content licensed from printed ISBN 10: 1284171329
Content licensed from printed ISBN 13: 978-1284171327
SUBSCRIPTION :
Please choose an auto renewable subscription plan to receive content access & continuous updates. Your subscription automatically renews as per your plan, so you always have the latest content.
Yearly auto-renewing payments - $69.99
Payment will be charged to your iTunes Account at confirmation of purchase. Subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Subscription may be managed by the user & auto-renewal can be disabled at any time by going to your device “Settings” and tapping “iTunes & App Store”. Any unused portion of a free trial period will be forfeited when you purchase a subscription, where applicable.
If you have any questions or comments, email us any time: customersupport@skyscape.com or call 508-299-30000
Privacy Policy-https://www.skyscape.com/terms-of-service/privacypolicy.aspx
Terms and Conditions-https://www.skyscape.com/terms-of-service/licenseagreement.aspx
Editor(s): Gail M. Wilkes, MS, APRN-BC, AOCN; Margaret Barton-Burke, PhD, RN, FAAN;
Publisher: Jones & Bartlett Learning
Quoi de neuf dans la dernière version ?
- Minor Bug Fixes
- UI-UX enhancements
